

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT NHI:</b> .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	.....	.....
Fax Number: .....	Fax Number: .....	

## Ambrisentan

### Initial application — PAH monotherapy

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months.

#### Prerequisites(tick boxes where appropriate)

<input type="checkbox"/> Patient has pulmonary arterial hypertension (PAH)																																	
<b>and</b>	<input type="checkbox"/> PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications																																
<b>and</b>	<input type="checkbox"/> PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV																																
<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> PAH has been confirmed by right heart catheterisation</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm<sup>-5</sup>)</td></tr><tr><td><b>and</b></td><td><table border="0"><tr><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures</td></tr><tr><td><b>and</b></td><td><table border="0"><tr><td><input type="checkbox"/> Ambrisentan is to be used as PAH monotherapy</td><td></td></tr><tr><td><b>and</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects with both sildenafil and bosentan</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease</td></tr></table></td></tr></table></td></tr></table>	<input type="checkbox"/> PAH has been confirmed by right heart catheterisation		<b>and</b>	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)	<b>and</b>	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg	<b>and</b>	<input type="checkbox"/> Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm <sup>-5</sup> )	<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH		<b>or</b>	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	<b>or</b>	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type	<b>or</b>	<input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease	<b>or</b>	<input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures	<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Ambrisentan is to be used as PAH monotherapy</td><td></td></tr><tr><td><b>and</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects with both sildenafil and bosentan</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease</td></tr></table></td></tr></table>	<input type="checkbox"/> Ambrisentan is to be used as PAH monotherapy		<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects with both sildenafil and bosentan</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease</td></tr></table>	<input type="checkbox"/> Patient has experienced intolerable side effects with both sildenafil and bosentan		<b>or</b>	<input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)	<b>or</b>	<input type="checkbox"/> Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease
<input type="checkbox"/> PAH has been confirmed by right heart catheterisation																																	
<b>and</b>	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)																																
<b>and</b>	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg																																
<b>and</b>	<input type="checkbox"/> Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm <sup>-5</sup> )																																
<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH		<b>or</b>	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	<b>or</b>	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type																										
<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH																																	
<b>or</b>	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**																																
<b>or</b>	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type																																
<b>or</b>	<input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease																																
<b>or</b>	<input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures																																
<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Ambrisentan is to be used as PAH monotherapy</td><td></td></tr><tr><td><b>and</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects with both sildenafil and bosentan</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease</td></tr></table></td></tr></table>	<input type="checkbox"/> Ambrisentan is to be used as PAH monotherapy		<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects with both sildenafil and bosentan</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease</td></tr></table>	<input type="checkbox"/> Patient has experienced intolerable side effects with both sildenafil and bosentan		<b>or</b>	<input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)	<b>or</b>	<input type="checkbox"/> Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease																						
<input type="checkbox"/> Ambrisentan is to be used as PAH monotherapy																																	
<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects with both sildenafil and bosentan</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease</td></tr></table>	<input type="checkbox"/> Patient has experienced intolerable side effects with both sildenafil and bosentan		<b>or</b>	<input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)	<b>or</b>	<input type="checkbox"/> Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease																										
<input type="checkbox"/> Patient has experienced intolerable side effects with both sildenafil and bosentan																																	
<b>or</b>	<input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)																																
<b>or</b>	<input type="checkbox"/> Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease																																

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT NHI:</b> .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	.....	.....
Fax Number: .....	.....	Fax Number: .....

**Ambrisentan** - *continued*

**Initial application — PAH dual therapy**

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months.

**Prerequisites**(tick boxes where appropriate)

<input type="checkbox"/> Patient has pulmonary arterial hypertension (PAH)															
<b>and</b>	<input type="checkbox"/> PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications														
<b>and</b>	<input type="checkbox"/> PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV														
<b>and</b>	<table border="1"><tr><td><input type="checkbox"/> PAH has been confirmed by right heart catheterisation</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm<sup>-5</sup>)</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	<input type="checkbox"/> PAH has been confirmed by right heart catheterisation		<b>and</b>	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)	<b>and</b>	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg	<b>and</b>	<input type="checkbox"/> Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm <sup>-5</sup> )	<b>or</b>	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH	<b>or</b>	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	<b>or</b>	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type
<input type="checkbox"/> PAH has been confirmed by right heart catheterisation															
<b>and</b>	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)														
<b>and</b>	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg														
<b>and</b>	<input type="checkbox"/> Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm <sup>-5</sup> )														
<b>or</b>	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH														
<b>or</b>	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**														
<b>or</b>	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type														
<b>or</b>	<input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease														
<b>or</b>	<input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures														
<b>and</b>	<table border="1"><tr><td><input type="checkbox"/> Ambrisentan is to be used as PAH dual therapy</td><td></td></tr><tr><td><b>and</b></td><td><table border="1"><tr><td><input type="checkbox"/> Patient has tried bosentan (either as PAH monotherapy, or PAH dual therapy with sildenafil) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has experienced intolerable side effects on bosentan</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and would benefit from initial dual therapy in the opinion of the treating clinician and has an absolute or relative contraindication to bosentan (eg. due to current liver disease or use of a combined oral contraceptive)</td></tr></table></td></tr></table>	<input type="checkbox"/> Ambrisentan is to be used as PAH dual therapy		<b>and</b>	<table border="1"><tr><td><input type="checkbox"/> Patient has tried bosentan (either as PAH monotherapy, or PAH dual therapy with sildenafil) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has experienced intolerable side effects on bosentan</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and would benefit from initial dual therapy in the opinion of the treating clinician and has an absolute or relative contraindication to bosentan (eg. due to current liver disease or use of a combined oral contraceptive)</td></tr></table>	<input type="checkbox"/> Patient has tried bosentan (either as PAH monotherapy, or PAH dual therapy with sildenafil) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**		<b>or</b>	<input type="checkbox"/> Patient has experienced intolerable side effects on bosentan	<b>or</b>	<input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)	<b>or</b>	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and would benefit from initial dual therapy in the opinion of the treating clinician and has an absolute or relative contraindication to bosentan (eg. due to current liver disease or use of a combined oral contraceptive)		
<input type="checkbox"/> Ambrisentan is to be used as PAH dual therapy															
<b>and</b>	<table border="1"><tr><td><input type="checkbox"/> Patient has tried bosentan (either as PAH monotherapy, or PAH dual therapy with sildenafil) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has experienced intolerable side effects on bosentan</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and would benefit from initial dual therapy in the opinion of the treating clinician and has an absolute or relative contraindication to bosentan (eg. due to current liver disease or use of a combined oral contraceptive)</td></tr></table>	<input type="checkbox"/> Patient has tried bosentan (either as PAH monotherapy, or PAH dual therapy with sildenafil) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**		<b>or</b>	<input type="checkbox"/> Patient has experienced intolerable side effects on bosentan	<b>or</b>	<input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)	<b>or</b>	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and would benefit from initial dual therapy in the opinion of the treating clinician and has an absolute or relative contraindication to bosentan (eg. due to current liver disease or use of a combined oral contraceptive)						
<input type="checkbox"/> Patient has tried bosentan (either as PAH monotherapy, or PAH dual therapy with sildenafil) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**															
<b>or</b>	<input type="checkbox"/> Patient has experienced intolerable side effects on bosentan														
<b>or</b>	<input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)														
<b>or</b>	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and would benefit from initial dual therapy in the opinion of the treating clinician and has an absolute or relative contraindication to bosentan (eg. due to current liver disease or use of a combined oral contraceptive)														

**I confirm the above details are correct and that in signing this form I understand I may be audited.**

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT NHI:</b> .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	.....	.....
Fax Number: .....	Fax Number: .....	

**Ambrisentan** - *continued*

**Initial application — PAH triple therapy**

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months.

**Prerequisites**(tick boxes where appropriate)

<input type="checkbox"/> Patient has pulmonary arterial hypertension (PAH)																																									
<b>and</b>	<input type="checkbox"/> PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications																																								
<b>and</b>	<input type="checkbox"/> PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV																																								
<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> PAH has been confirmed by right heart catheterisation</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm<sup>-5</sup>)</td></tr><tr><td><b>and</b></td><td><table border="0"><tr><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures</td></tr><tr><td><b>and</b></td><td><table border="0"><tr><td><input type="checkbox"/> Ambrisentan is to be used as PAH triple therapy</td><td></td></tr><tr><td><b>and</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient is on the lung transplant list</td><td></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr></table></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table></td></tr></table></td></tr></table></td></tr></table>	<input type="checkbox"/> PAH has been confirmed by right heart catheterisation		<b>and</b>	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)	<b>and</b>	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg	<b>and</b>	<input type="checkbox"/> Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm <sup>-5</sup> )	<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH		<b>or</b>	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	<b>or</b>	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type	<b>or</b>	<input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease	<b>or</b>	<input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures	<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Ambrisentan is to be used as PAH triple therapy</td><td></td></tr><tr><td><b>and</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient is on the lung transplant list</td><td></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr></table></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table></td></tr></table></td></tr></table>	<input type="checkbox"/> Ambrisentan is to be used as PAH triple therapy		<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Patient is on the lung transplant list</td><td></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr></table></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table></td></tr></table>	<input type="checkbox"/> Patient is on the lung transplant list		<b>or</b>	<table border="0"><tr><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr></table>	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV		<b>and</b>	<input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)	<b>or</b>	<table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table>	<input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**		<b>and</b>	<input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario
<input type="checkbox"/> PAH has been confirmed by right heart catheterisation																																									
<b>and</b>	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)																																								
<b>and</b>	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg																																								
<b>and</b>	<input type="checkbox"/> Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm <sup>-5</sup> )																																								
<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td><td></td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td><b>or</b></td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH		<b>or</b>	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	<b>or</b>	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type																																		
<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH																																									
<b>or</b>	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**																																								
<b>or</b>	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type																																								
<b>or</b>	<input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease																																								
<b>or</b>	<input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures																																								
<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Ambrisentan is to be used as PAH triple therapy</td><td></td></tr><tr><td><b>and</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient is on the lung transplant list</td><td></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr></table></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table></td></tr></table></td></tr></table>	<input type="checkbox"/> Ambrisentan is to be used as PAH triple therapy		<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Patient is on the lung transplant list</td><td></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr></table></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table></td></tr></table>	<input type="checkbox"/> Patient is on the lung transplant list		<b>or</b>	<table border="0"><tr><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr></table>	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV		<b>and</b>	<input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)	<b>or</b>	<table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table>	<input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**		<b>and</b>	<input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario																						
<input type="checkbox"/> Ambrisentan is to be used as PAH triple therapy																																									
<b>and</b>	<table border="0"><tr><td><input type="checkbox"/> Patient is on the lung transplant list</td><td></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr></table></td></tr><tr><td><b>or</b></td><td><table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table></td></tr></table>	<input type="checkbox"/> Patient is on the lung transplant list		<b>or</b>	<table border="0"><tr><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr></table>	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV		<b>and</b>	<input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)	<b>or</b>	<table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table>	<input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**		<b>and</b>	<input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario																										
<input type="checkbox"/> Patient is on the lung transplant list																																									
<b>or</b>	<table border="0"><tr><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)</td></tr></table>	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV		<b>and</b>	<input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)																																				
<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV																																									
<b>and</b>	<input type="checkbox"/> Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease)																																								
<b>or</b>	<table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td><b>and</b></td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table>	<input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**		<b>and</b>	<input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario																																				
<input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**																																									
<b>and</b>	<input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario																																								

**I confirm the above details are correct and that in signing this form I understand I may be audited.**

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT NHI:</b> .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	.....	.....
Fax Number: .....	Fax Number: .....	

**Ambrisentan** - *continued*

**Renewal**

Current approval Number (if known):.....

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years.

**Prerequisites**(tick box where appropriate)

The patient is continuing to derive benefit from ambrisentan treatment according to a validated PAH risk stratification tool\*\*

Note: \*\* the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

**I confirm the above details are correct and that in signing this form I understand I may be audited.**

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)